Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00056745 · ClinicalTrials.gov registry record · Phase 1
Determining an Effective Site (Groin Versus Arm) for Giving HIV Vaccines
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00056745 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 12 participants.
The verdict
NCT00056745, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and immune system response to the TBC-3B HIV vaccine when it is injected either into the groin area or into the arm. The goal is to determine which injection site is better at producing a particular type of immune response. This study is not evaluating the effectiveness of the vaccine, so volunteers must maintain low risk behavior for HIV transmission throughout the study.
Interventions
- BIOLOGICAL TBC-3B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00056745
The ClinicalTrials.gov registry entry for NCT00056745 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TBC-3B is the first listed.
NCT00056745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00056745 about?
NCT00056745 is a clinical study titled "Determining an Effective Site (Groin Versus Arm) for Giving HIV Vaccines". The purpose of this study is to determine the safety and immune system response to the TBC-3B HIV vaccine when it is injected either into the groin area or into the arm. The goal is to determine which injection site is better at producing a particular type of immune response. This study is not evalu...
What is the current status of trial NCT00056745?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants.
What interventions are being tested in trial NCT00056745?
The interventions under investigation include: TBC-3B (BIOLOGICAL).
Who is sponsoring clinical trial NCT00056745?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.